MindMed Appoints Francois Lilienthal As New CCO

With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. MNMD as chief commercial officer (CCO). He had been serving as a consultant for the company for the last six months.

Lilienthal has a long trajectory with pharmaceutical companies—in 1997, he was Associate Medical Director for Rhone-Poulenc Rorer in Japan and later joined Bristol Myers Squibb BMY, where he was director and Global Marketing Leader.

In 2003, he started his work at the Janssen Pharmaceutical Companies of Johnson & Johnson JNJ as executive director and Global Marketing Leader. From 2005 to 2007, Lilienthal served as executive director and U.S. Brand Leader at Tibotec, leading the launch of three HIV brands and the launch of Prezista, which achieved $800M in annual revenues at its peak. For the next 14 years, Lilienthal would be part of Merck MRK, where he held several executive positions, including Vice President, General Manager for Virology, and Global Commercial Leader for Early Development.

This is a pivotal time for the industry and I am honored to be joining MindMed,” the new CCO commented. “I believe there is potential for psychedelic-derived medicine to address brain health disorders and look forward to working closely with the executive team as we continue conversations with the FDA and advance MindMed through its next phase of growth.”

“Dr. Lilienthal's expertise in growing businesses through successful global product launches across a range of therapeutic indications will be critical as we advance our pipeline and seek to address the massive need for novel therapies”, added Robert Barrow, MindMed’s CEO.

This year, at the upcoming Benzinga Psychedelics Capital Conference, to be held on April 19 at the Fontainebleau Miami Beach Hotel in Florida, Robert Barrow will share his vision and valuable insights about the burgeoning sector.

Photo: Courtesy of Photo by Chris Liverani on Unsplash

Posted In: CannabisNewsPenny StocksPsychedelicsSmall CapManagementMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.